Table 3.
SII-ChAdOx1 nCoV-19 (N = 1,200) n (%) [E] |
Placebo (N = 300) n (%) [E] |
AZD1222 (N = 100) n (%) [E] |
|
---|---|---|---|
Any AE within 30 minutes after vaccination | 15 (1.3) [16] | 4 (1.3) [5] | 0 |
Any AE | 352 (29.3) [602] | 72 (24.0) [101] | 20 (20.0) [32] |
Severe | 3 (0.3) [3] | 1 (0.3) [1] | 0 |
Any treatment-related AE | 236 (19.7) [384] | 39 (13.0) [50] | 0 |
Any SAE | 21 (1.8) [21] | 4 (1.3) [4] | 2 (2.0) [2] |
Related SAE | 0 | 0 | 0 |
AE, adverse event; E, number of events; n, participants reporting at least one AE; N, total number of participants in a group; SAE, serious adverse event.